Could a shot every two weeks beat weekly diabetes drugs?

NCT ID NCT07628985

Not yet recruiting Disease control Sponsor: Carnot Laboratories Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new medicine called bofanglutide (GZR18) for adults with type 2 diabetes whose blood sugar is not well controlled with metformin alone. Bofanglutide is given as a shot under the skin every two weeks, and researchers compare it to semaglutide, a weekly injection. The goal is to see if bofanglutide can lower blood sugar as effectively and safely as semaglutide over 30 weeks. About 374 Latin American adults will take part, continuing their metformin while receiving either bofanglutide or semaglutide.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bofanglutide (GZR18)
What this could lead to: If successful, bofanglutide could offer a convenient every-two-week injection option for managing type 2 diabetes, potentially improving treatment adherence.
What could go wrong: This is a Phase 3 trial, so results are not yet confirmed. Bofanglutide may not prove as effective or safe as semaglutide, and side effects common to GLP-1 drugs (e.g., nausea, vomiting) are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS (T2DM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES MELLITUS (T2DM)

Contacts and locations

Locations

Arechavaleta Granell Maria del Rosario Consultorio de Medicina Especializada

Guadalajara, Jalisco, 44650, Mexico
Asociación Mexicana para la Investigación Clínica A.C. AMIC

Pachuca, Hidalgo, 42082, Mexico
Instituto Jalisciense de Investigación en Diabetes y Obesidad, S.C.

Guadalajara, Jalisco, 44600, Mexico
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran

Mexico City, 14080, Mexico
Oaxaca Site Management Organization, S.C.

Oaxaca City, Oaxaca, 68000, Mexico
Private Practice

Mexico City, Cuauhtémoc, 06700, Mexico
Universidad Autónoma de Nuevo Leon. Facultad de Medicina

Monterrey, Nuevo León, 64460, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.